Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Reduced frequency is very encouraging for patient compliance and could help those who dislike weekly injections and ...

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...